Compare TR & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | LIVN |
|---|---|---|
| Founded | 1896 | 1987 |
| Country | United States | United Kingdom |
| Employees | 2300 | N/A |
| Industry | Specialty Foods | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | N/A | 2015 |
| Metric | TR | LIVN |
|---|---|---|
| Price | $42.42 | $58.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $72.43 |
| AVG Volume (30 Days) | 125.7K | ★ 892.5K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.15 |
| Revenue Next Year | N/A | $6.67 |
| P/E Ratio | $32.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.13 | $32.48 |
| 52 Week High | $44.27 | $71.58 |
| Indicator | TR | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 29.71 |
| Support Level | $41.55 | $49.51 |
| Resistance Level | $43.36 | $58.91 |
| Average True Range (ATR) | 1.29 | 2.30 |
| MACD | -0.22 | -1.17 |
| Stochastic Oscillator | 56.55 | 3.76 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.